At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 106 enrolled
Drug / intervention
Reslizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Efficacy and Safety Study of Reslizumab in the Treatment of Poorly Controlled Asthma in Subjects With Eosinophilic Airway Inflammation
In Brief
A Phase 2 clinical trial evaluating Reslizumab and Saline for Asthma. Completed, enrolled 106 participants across 30 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the effectiveness and safety of reslizumab in the treatment of subjects with poorly controlled asthma.
Study Details
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2008
Enrollment StartApr 2008
Primary CompletionMar 2010
TodayJul 2026
First PostedJan 7, 2008
Enrollment StartApr 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.5 years ago
Interventions
Reslizumabbiological
Salineother